All products are HSA/FSA eligible | Free Shipping $79 & up
Heart health, fatty liver, metabolic health, diabetes, insulin resistance, inflammation, longevity

Better health comes from smarter testing.

Don’t let Insulin Resistance, Heart Disease or Fatty Liver develop and progress undetected.

CardioMetaboliQ employs 10 validated “smart index” biomarkers to help you better understand your risks. Better yet, you’ll get validated action steps showing you how to naturally reduce your risks and optimize your healthspan!

Cardiometaboliq home blood test

Are blood tests from the 1970’s really your best choice for your annual check up?


Science has come a long way since then. Current research shows us so much more about our health, and how to protect it. And CardioMetaboliQ delivers leading-edge heart, liver and metabolic testing at home.

CardioMetaboliQ Home Blood Test: $199 (HSA/FSA approved)

One major reason why 93% of US adults are not in optimal cardiometabolic health is a lack of informative, actionable testing in cardiometabolic health (liver, heart, metabolism).

For example, did you know that Fatty Liver can double Diabetes risk, and can increase Heart Disease risk by 50%? Yet CardioMetaboliQ is the only test that includes the Fatty Liver Index (FLI).


Because the “normal” ranges used on blood tests haven’t caught up with current research, substantial (and manageable) risks exist even with results well within “normal range”. Such as…

- a 30-70% increase in relative risk for Alzheimer’s Disease with “normal range” Triglycerides and Glucose (TyG):
Association of TyG Index with Risk of Alzheimer’s Disease

- a 50% increase in relative risk for ASCVD (heart disease) with NAFLD (Fatty Liver):
Fatty Liver Increases Risk for ASCVD (heart disease)

- a >50% increase in risk for Heart Attack
with “normal range” Triglyceride and Glucose (TyG): Association between TyG and Myocardial Infarction (heart attack)


Watch the Video Overview: CardioMetaboliQ + MetaVasc Overview

The CardioMetaboliQ Health Report empowers you to stay healthy naturally. And the patented ingredients in proprietary MetaVasc capsules naturally support healthy heart, liver and metabolic function. Additionally, a key MetaVasc ingredient, Bergacyn, is clinically shown to boost weight loss 60-90% and reduce liver fat by 50% over dieting alone in a 12 week study.(1)

Your doctor may be a bit too busy…

We’ve all heard the words: “Your labs are normal..”. But what does that actually mean? Unfortunately, it can mean “we didn’t look at very much, and so we didn’t notice anything.”

Frankly, the economics of efficiency in primary care medicine just don’t support the extra time (cost) it takes to really deliver a comprehensive heart, liver and metabolic blood panel and analysis.

CardioMetaboliQ is different. CardioMetaboliQ is for thinkers. Those of us that don’t just assume everything is fine. We would rather understand our health and take action than sit back and assume “healthcare” has us covered.

CardioMetaboliQ’s 12 page personalized report dives deeply into the interconnected relationships between the body systems, and how they affect disease, together.

CardioMetaboliQ is the only test available (home or lab based) that measures the Fatty Liver Index, 2 advanced insulin sensitivity markers, inflammation, 4 residual heart risk markers, visceral fat, oxidative stress and more.

So, if you’re going to test, test smart. Test with CardioMetaboliQ.

Heart Health

CardioMetaboliQ looks beyond simple LDL/HDL and Triglycerides. Checking Remnant Cholesterol, Atherogenic Index, CRP, and TyG; superior markers for residual heart risk.

Brain Health

Insulin sensitivity and glucose metabolism, even liver health, are all critical to neurocognitive health. CardioMetaboliQ accurately tests all of these areas so you know your risks.

Metabolic Health

Insulin Sensitivity and low visceral fat content are the keys to cardiometabolic health and wellness. So CardioMetaboliQ tests the most well-validated index, the Triglyceride-Glucose Index with and without visceral fat: TyG and TyG-WHtR.

Liver Health

CardioMetaboliQ is the only blood test that calculates the Fatty Liver Index. This crucial marker can help illuminate associated risk areas in vascular, metabolic and hepatic health. (22)

A lab report made for you, the patient.

Wouldn’t it be nice if someone patiently explained your health? From the big picture down to the important details?

Giving you plenty of time to digest the information, circle back and review?

Better still, providing you with clear, clinically validated action steps you could use to make and measure real improvement!

That’s what we do. CardioMetaboliQ.

No doctor’s appointment. No lab visit. Just valuable health insight.

No doctor’s appointment. No lab visit. Just valuable health insight.

At Home Convenience only $199

FAQ’s & References

Website References
Any footnotes located throughout this site denote information sourced from peer reviewed published scientific research located on Pubmed.
(1) Ferro, Yvelise et al. “Randomized Clinical Trial: Bergamot Citrus and Wild Cardoon Reduce Liver Steatosis and Body Weight in Non-diabetic Individuals Aged Over 50 Years.”Frontiers in endocrinologyvol. 11 494. 11 Aug. 2020, doi:10.3389/fendo.2020.00494

(2)Hua J, Malinski T. Variable Effects Of LDL Subclasses Of Cholesterol On Endothelial Nitric Oxide/Peroxynitrite Balance – The Risks And Clinical Implications For Cardiovascular Disease.Int J Nanomedicine. 2019;14:8973-8987https://doi.org/10.2147/IJN.S223524

(3) Quispe, Renato et al. “Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.”European heart journal, vol. 42,42 (2021): 4324-4332. doi:10.1093/eurheartj/ehab432
(4) Castañer O, Pintó X, Subirana I, et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease.J Am Coll Cardiol. 2020;76(23):2712-2724. doi:10.1016/j.jacc.2020.10.008
(5) Mangalesh S, Yadav P, Dudani S, Mahesh NK. Atherogenic index of plasma predicts coronary artery disease severity and major adverse cardiac events in absence of conventional risk factors.Coron Artery Dis. 2022;33(7):523-530. doi:10.1097/MCA.0000000000001166
(6)https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease
(7) Musolino, Vincenzo et al. “The synergistic effect ofCitrus bergamiaandCynara cardunculusextracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease.”Journal of traditional and complementary medicinevol. 10,3 268-274. 8 Feb. 2020, doi:10.1016/j.jtcme.2020.02.004
(8)https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
(9) Sun J, Xie Z, Wu Y, et al. Association of the Triglyceride-Glucose Index With Risk of Alzheimer's Disease: A Prospective Cohort Study [published online ahead of print, 2023 Jul 26].Am J Prev Med. 2023;S0749-3797(23)00312-4. doi:10.1016/j.amepre.2023.07.011
(10)https://www.cdc.gov/heartdisease/facts.htm#:~:text=Every%20year%2C%20about%20805%2C000%20people,States%20have%20a%20heart%20attack.&text=Of%20these%2C,are%20a%20first%20heart%20attack.
(11) Reijnders E, van der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. Front Cardiovasc Med. 2023 Oct 16;10:1264319. doi: 10.3389/fcvm.2023.1264319. PMID: 37908502; PMCID: PMC10613690.
(12) Freeman AM, Acevedo LA, Pennings N. Insulin Resistance. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK507839/
(13) Cordero, Alberto et al. “The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.”Journal of clinical lipidology, S1933-2874(23)00252-0. 22 Aug. 2023, doi:10.1016/j.jacl.2023.08.006
(14) Moon, Joon Ho et al. “Triglyceride-Glucose Index Predicts Future Atherosclerotic Cardiovascular Diseases: A 16-Year Follow-up in a Prospective, Community-Dwelling Cohort Study.”Endocrinology and metabolism (Seoul, Korea)vol. 38,4 (2023): 406-417. doi:10.3803/EnM.2023.1703
(15) Xuan, Wenting et al. “Impacts of Triglyceride Glucose-Waist to Height Ratio on Diabetes Incidence: A Secondary Analysis of A Population-Based Longitudinal Data.”Frontiers in endocrinologyvol. 13 949831. 22 Jul. 2022, doi:10.3389/fendo.2022.949831
(16) Basheer, Maamoun et al. “Liver Fat Storage Is a Better Predictor of Coronary Artery Disease than Visceral Fat.”Metabolitesvol. 13,8 896. 28 Jul. 2023, doi:10.3390/metabo13080896
(17) O'Hearn, Meghan et al. “Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018.”Journal of the American College of Cardiology, vol. 80,2 (2022): 138-151. doi:10.1016/j.jacc.2022.04.046
(18) Li C, Guo P, Zhang R, et al. Both WHR and FLI as Better Algorithms for Both Lean and Overweight/Obese NAFLD in a Chinese Population.J Clin Gastroenterol. 2019;53(6):e253-e260. doi:10.1097/MCG.0000000000001089
(19) Garg, Ravi et al. “The Atherogenic Index of Plasma is Independently Associated with Symptomatic Carotid Artery Stenosis.”Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Associationvol. 29,12 (2020): 105351. doi:10.1016/j.jstrokecerebrovasdis.2020.105351
(20) Huang Q, Liu Z, Wei M, Huang Q, Feng J, Liu Z, Xia J. The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China. Cardiovasc Diabetol. 2023 May 27;22(1):125. doi: 10.1186/s12933-023-01839-y. Erratum in: Cardiovasc Diabetol. 2023 Sep 7;22(1):246. PMID: 37244995; PMCID: PMC10225098.
(21) Cordero, Alberto et al. “The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events.”Journal of clinical lipidologyvol. 17,5 (2023): 602-611. doi:10.1016/j.jacl.2023.08.006
(22) Xiao, Jieling et al. “Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD - An Umbrella Overview of Systematic Review of Meta-Analysis.”Journal of clinical and experimental hepatologyvol. 13,4 (2023): 656-665. doi:10.1016/j.jceh.2022.11.006
How big a problem is cardiometabolic disease?

-A survey of 55,000 adults from 1999-2018 by O’Hearn et al, found that 93.2% of US adults were in “less than optimal cardiometabolic health”.(17)

-Of the ~2 million annual US deaths from disease, 85-90% of these diseases are either initiated, perpetuated and/or worsened by cardiometabolic dysfunction.

-The annual cost of cardiometabolic disease in the United States is currently about $500 billion, and rising. Effectively testing cardiovascular, liver and metabolic systems together can provide timely awareness to reduce risk of disease progression.

-Cardiometabolic health is assessed based on liver, cardiovascular and metabolic health. Metabolic health refers primarily to blood sugar and lipid metabolism and, when dysfunctional, leads to prediabetes, diabetes, insulin resistance and metabolic syndrome. Neurological conditions such as Alzheimer’s Disease and neurocognitive decline and dementia are also closely related to metabolic disease.

-Liver diseases such as Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Hepatic Steatosis, cirrhosis and liver cancer are closely associated with hepato-cardiometabolic physiology and disease.

-Cardiovascular diseases including coronary artery disease, atherosclerosis and peripheral arterial disease are also a part of cardiometabolic disease. These conditions are generally worsened by metabolic and liver dysfunction.

What makes CardioMetaboliQ™️ better or different than other testing?

When compared to standard blood lab testing performed during routine annual physical exams, the CardioMetaboliQ test and health report can be said to offer a far more detailed analysis and interpretation. The CardioMetaboliQ test is designed based on the most current research, while the standard blood panels were actually created in the 1970’s.

Many of the markers on routine testing is indeed of value, but falls significantly short in terms of leveraging current risk assessment research.

Three compelling examples of this shortcoming are as follows:

1) Routine testing assesses LDL, HDL and Total Cholesterol along with Triglycerides. The primary determinants of cardiovascular risk are reported as LDL Cholesterol, with some emphasis on Triglycerides. While these markers are of value, current research strongly invalidates the reliance on LDL Cholesterol as a primary marker for heart disease. In fact, between 50-75% of all heart attacks occur in people with normal or only moderately elevated LDL Cholesterol. And control of LDL Cholesterol with statin medications only prevents ~17% of heart attacks, and ~6% of cardiovascular deaths. CardioMetaboliQ tests and reports optimal ranges for more useful markers and indexes, including Remnant Cholesterol, Atherogenic Index of Plasma, C Reactive Protein and Triglyceride Glucose Index. All of these markers are tested and shown to deliver substantially better risk assessment for heart attack, stroke and other cardiovascular diseases.

2) Liver health is very much at the forefront of cardiometabolic health. Indeed NAFLD (aka Fatty Liver) has wide ranging and serious upimpact on heart disease, cancer, metabolic diseases like diabetes and kidney disease. Routing blood tests include two “liver enzyme” markers, ALt and AST. While these markers are useful for some liver/gall bladder disease assessment, they are NOT clinically correlated with NAFLD. The accurate assessment of NAFLD requires a thoroughly validated index known as the Fatty Liver Index (aka FLI). Only the FLI is able to accurately diagnose fatty liver and provide the doctor and patient with insight into liver and related heart, kidney, cancer and metabolic disease risks.

3) Insulin Resistance is the earliest manifestation of cardiometabolic disease and dysfunction. The best way to test Insulin Resistance is by use of the Triglyceride-Glucose Index (aka TyG). Not only is the TyG not reported on standard blood panels, we actually find that “normal” levels of Triglycerides and fasting glucose (below 150 mg/dl and below 99 mg/dl respectively), when calculated to assess TyG, would allow for a high risk TyG level of 8.9. As reference, large studies show substantially increased elative risk for Alzheimer’s Disease with TyG over 8.7 as compared to TyG of 8.3 or lower. This increased risk is a whopping 70%.

These three examples of the shortcomings of routine blood testing for cardiometabolic disease are just a sample of the misalignment of health and routine blood testing.

CardioMetaboliQ is designed to give the user the fullest representation of their heart, vascular, hepatic and metabolic health and health risk.

What is MetaVasc®️?

MetaVasc®️ is a proprietary formula that blends therapeutic doses of the 4 most significant natural botanical ingredients to support cardiometabolic health.

Blending citrus bergamot, wild cynara artichoke, high bioavailability curcumin and berberine together, MetaVasc®️ingredients are clinically proven to support healthy levels of:

- cholesterol - inflammation - blood sugar - oxidative stress - vascular endothelial function - liver fat - fat visceral fat - body composition - weight - liver function - triglycerides - uric acid- and more.

Additional ingredients are PQQ and Chromium Picolinate.

What is tested on the CardioMetaboliQ™️ test.

Here’s a partial list of the markers and indexes tested as well as risk index values that can be calculated using the BioCalculators on this website.

Inflammation (hsCRP) - Fatty Liver Index - Anthropometric Insulin Resistance Indexes - Hemoglobin A1C - Visceral Fat - Metabolic Syndrome Score Calculator - GGT - Fasting Glucose - LDL - HDL - TC -  TG - ASCVD Heart Risk Calculator - - Liver Function - Oxidative Stress Index - Body Composition - Metabolic Rate Calculator - CardioMetaboliQ™️ Index..and more!

Who is the CardioMetaboliQ™️ test good for?

The CardioMetaboliQ™️ test and health report can be of substantial value to almost anyone over the age of 12. With the early onset of metabolic diseases like insulin resistance, prediabetes and fatty liver in the US, we see benefit I. Assessment of even young people if weight, body composition or metabolic issues are a concern.

Clearly CardioMetaboliQ testing is a logical assessment for adults managing less than optimal cardiometabolic health. And shockingly, a large 2018 survey of 55,000 US adults from 1999-2018 found that 93.2% of the subjects were in “less than optimal cardiometabolic health”.(17)

As such, almost all US adults could likely gain some important insights and learn some useful tools regarding their cardiometabolic health and risks.

What is Residual Heart Disease Risk?

Statistics show that a large percentage of patients that have heart attacks, strokes and other cardiovascular diseases and events do not have unhealthy levels of LDL cholesterol. This includes people who are on statin medications which maintain their LDL levels in the proposed healthy range (<100 or lower).

In the cardiovascular research, the risk that causes these “healthy heart attacks” is referred to as “residual risk”, that is, the risk that remains after standard therapeutic approaches have been applied (eg statin drugs to lower LDL cholesterol).

▪️Each year, roughly 600,000 US adults have “healthy heart attacks” with “normal” blood cholesterol levels. That equates to more than 1 heart attack every minute.(2)

▪️And almost 75% of the people who have heart attacks do not have dangerous levels of LDL cholesterol.(2)

▪️Unfortunately, large studies now confirm that statin medications only reduce heart attack risk by 17% and cardiovascular death by only 6% vs placebo.(13)

-So, CardioMetaboliQ tests the markers that are known to correlate with “residual risk”.

Markers that better reflect this residual risk include: Remnant Cholesterol, C Reactive Protein, Atherogenic Index of Plasma, Fatty Liver Index and
Triglyceride-Glucose Index. These markers are advanced cardiovascular risk indicators which reveal residual heart disease risk more completely than LDL cholesterol alone.(3,4,5)

Studies now confirm that Atherogenic index of Plasma (AIP) correlates well as a surrogate marker for the damaging subtype of LDL known as small dense LDL, sdLDL. There is a strong correlation between carotid artery stenosis and sdLDL and AIP levels.(19,20)

Remnant Cholesterol (RC)is shown in studies to reflect “residual” atherosclerotic risk better than LDL cholesterol, and even more accurately than ApoB levels.(3)

What is Insulin Resistance and why is it important?

-Insulin Resistance refers to the reduced capacity for the body to respond to insulin signaling and thereby maintain appropriate blood sugar regulation and metabolic homeostasis.

-Insulin Resistance is critically important because it often begins many years in advance of other metabolic conditions such as prediabetes, metabolic syndrome and diabetes.

What is Fatty Liver Disease and why is it important?

Fatty Liver Disease refers to an increase in the concentration of fat deposits in the liver, generally brought about by excess caloric intake and insufficient exercise. Many people with this condition are unaware that they have it.

More than 80 million Americans have Non Alcoholic Fatty Liver Disease (NAFLD), a condition which can worsen diabetes and heart disease, and increases risk of liver and other cancers.(6)

-So we provide the Fatty Liver Index to check liver fat content and assess whether NAFLD may be an concern.(16,18)

-MetaVasc®️Capsules contain a branded patented ingredient called BergacynFF, which has been clinically shown in human studies to reduce liver fat levels and improve several cardiometabolic parameters including inflammation, cholesterol, blood sugar, body weight, BMI, oxidative stress and vascular endothelial function.

Is Alzheimer’s Disease affected by cardiometabolic health?

-Alzheimer’s Disease is sometimes referred to as Type 3 Diabetes, because the effects of glycemic dysregulation (blood sugar mismanagement) are strongly seen as contributing to Alzheimer’s Disease progression and the risk and development of other neurocognitive conditions.

More than 6 million US adults have Alzheimer’s Disease.(8)

-Studies indicate that Alzheimer’s risk can be as much as 69% higher with elevated Insulin Resistance (TyG), even with blood lab results considered to be within standard or “normal” range.(9)

Click to see BioCalculators and Related Research


The calculators below can be a great way to see how your health risks can be improved by changes to personal health characteristics.

By using the results from your CardioMetaboliQ™️ blood test, you can calculate various health risk profiles for yourself, like atherosclerosis, diabetes and fatty liver.

Then, by projecting improvements in areas like waist size, cholesterol and triglyceride levels, blood sugar, and blood pressure, you can target reductions in your health risks.


CardioPredict™️ BioCalculators

1) Atherosclerosis (ASCVD) Risk Assessment Calculator

https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/advice/riskgraph/

2) Fatty Liver Index (FLI) Calculator

https://www.mdapp.co/fatty-liver-index-fli-calculator-356/

3) Triglyceride-Glucose Index (TyG) Calculator

https://dremilyfranklin.com/triglyceride-glucose-index/

4) Atherogenic Index of Plasma (AIP) Calculator

https://www.evidencio.com/models/show/1141

5) Findrisc Diabetes Risk Calculator

https://reference.medscape.com/calculator/236/findrisc-diabetes-risk-calculator

6) Carbohydrate Intake for Weight Management Calculator

https://www.mdapp.co/carbs-calculator-daily-carbohydrate-intake-220/

7) Body Mass Index (BMI) Calculator

https://www.mdapp.co/bmi-calculator-64/

Related Research Studies

The studies listed below apply the markers found in the CardioMetaboliQ™️ test to different health conditions.

(to open studies, copy & paste the bold “doi” link into PubMed search bar)

1) Zhou, Jing et al. “Fatty Liver Index and Its Association with 10-Year Atherosclerotic Cardiovascular Disease Risk: Insights from a Population-Based Cross-Sectional Study in China.” Metabolitesvol. 13,7 850. 14 Jul. 2023, doi:10.3390/metabo13070850

2) Weaver, Olivia R et al. “Nonfasting remnant cholesterol and cardiovascular disease risk prediction in Albertans: a prospective cohort study.”CMAJ openvol. 11,4 E645-E653. 25 Jul. 2023, doi:10.9778/cmajo.20210318

3) Sun, Junyi et al. “Association of the Triglyceride-Glucose Index With Risk of Alzheimer's Disease: A Prospective Cohort Study.”American journal of preventive medicine, S0749-3797(23)00312-4. 26 Jul. 2023, doi:10.1016/j.amepre.2023.07.011

4) Tarantino, Giovanni et al. “Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study.”Journal of clinical medicinevol. 10,2 346. 18 Jan. 2021, doi:10.3390/jcm10020346

5) Ding, Xiaobo et al. “Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies.”Cardiovascular diabetologyvol. 20,1 76. 3 Apr. 2021, doi:10.1186/s12933-021-01268-9

6) Reijnders E, van der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. Front Cardiovasc Med. 2023 Oct 16;10:1264319. doi: 10.3389/fcvm.2023.1264319. PMID: 37908502; PMCID: PMC10613690.

7) Huang, Qin et al. “Association of novel lipid indicators with the risk of stroke among participants in Central China: a population-based prospective study.”Frontiers in endocrinologyvol. 14 1266552. 2 Oct. 2023, Huang, Qin et doi:10.3389/fendo.2023.1266552

8) Zhang, Peng et al. “The Role of Remnant Cholesterol Beyond Low-Density Lipoprotein Cholesterol in Arterial Stiffness: A Cross-Sectional Study.”Metabolic syndrome and related disorders, 10.1089/met.2023.0101. 30 Oct. 2023, doi:10.1089/met.2023.0101

How do I take my test & get my results?

Taking the test:
After an 8 hour fasting period, follow the instructions in the lab kit. Prick your finger (lancets included), and place 4-5 drops of blood on the ADX-100 card; watch to make sure the blood travels to the required line. Then mail your sample to the lab in the postage paid package. We highly recommend that you watch the instructional video for tips to make the sample process fast and easy.

Getting your results:
We include priority prepaid postage for quick turn-around, so you will have your results within just 2-5 days of mailing in your sample. You’ll be able to access your lab results on your smart phone, and you will also receive an email with a link for you to retrieve and download your 12 page personalized report from our secure server.

Testing by Clinical Reference Laboratories Corporation